Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com

Zosuquidar trihydrochloride

Catalog No.: 52003
Cas No.: 167465-36-3
Purity : 99% 

zosuquidar trihydrochloride is a difluorocyclopropyl quinoline. Zosuquidar trihydrochloride binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents.

zosuquidar trihydrochloride, Bulk in stock, contact us by email for the quotation.

For research use only. We do not sell to patients.

Chemical Information

名称Zosuquidar trihydrochloride
Iupac 化学名称(2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol trihydrochloride 
同义词LY 335979; LY-335979; LY335979; D06387; RS33295198; Zosuquidar HCl; Zosuquidar 3HCl; Zosuquidar trihydrochloride
英文同义词LY 335979; LY-335979; LY335979; D06387; RS33295198; Zosuquidar HCl; Zosuquidar 3HCl; Zosuquidar trihydrochloride
分子式C32H31F2N3O2.3HCl 
分子量636.99 
Smilec1ccc2c(c1)[C@@H](c3ccccc3[C@@H]4[C@H]2C4(F)F)N5CCN(CC5)C[C@H](COc6cccc7c6cccn7)O
InChiKeyIHOVFYSQUDPMCN-DBEBIPAYSA-N
InChiInChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m1/s1
Cas号167465-36-3
MDLMFCD09837761
Related CAS167465-36-3 ( HCl) 167354-41-8 (free base)

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
BulkEnquiryEnquiryEnquiry
Request Bulk Quote Download MSDS 电话 : +86-27-65522453   Email : sales@sun-shinechem.com
Formulationlight yellow to off-white solid 
纯度99% 
存储3 years -20ºCpowder 6 months-80ºCin solvent 
可溶性5mg/ml in DMSO 
Handling
运输条件Shipped under ambient temperature 
HS Code
Coming soon.
Targets
Mechanism
Cell study
Animal study
Clinical study

1. Alam A, Küng R, Kowal J, McLeod RA, Tremp N, Broude EV, Roninson IB, Stahlberg H, Locher KP.Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1973-E1982. doi: 10.1073/pnas.1717044115. Epub 2018 Feb 13.

2. Battistella C, Klok HA.Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. Biomacromolecules. 2017 Jun 12;18(6):1855-1865. doi: 10.1021/acs.biomac.7b00291. Epub 2017 May 4.

3. Abu Ajaj K1, Graeser R, Kratz F.Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells and an albumin-binding prodrug. Breast Cancer Res Treat. 2012 Jul;134(1):117-29. doi: 10.1007/s10549-011-1937-9. Epub 2012 Jan 8.

4. Briglia M, Fazio A, Faggio C, Lang F.Triggering of Suicidal Erythrocyte Death by Zosuquidar.

Cell Physiol Biochem. 2015;37(6):2355-65. doi: 10.1159/000438589. Epub 2015 Dec 7.

Abstract

BACKGROUND:

The P-glycoprotein inhibitor zosuquidar (LY335979) is clinically used to augment the effect of cytostatic drugs on suicidal tumor cell death or apoptosis. The present study explored whether the substance is cytotoxic to erythrocytes. Upon injury, erythrocytes may undergo suicidal cell death or eryptosis, which is characterized by cell shrinkage and translocation of cell membrane phosphatidylserine to the erythrocyte surface. Signaling of eryptosis include increase of cytosolic Ca2+-activity ([Ca2+]i), oxidative stress and activation of several kinases, such as p38 kinase and protein kinase C.

METHODS:

Phosphatidylserine abundance at the erythrocyte surface was quantified from binding of FITC-labelled annexin-V, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, and reactive oxygen species (ROS) from 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) fluorescence.

RESULTS:

A 48 h treatment of human erythrocytes with zosuquidar significantly increased the percentage of annexin-V-binding cells (2 and 4 µg/ml), significantly decreased forward scatter (4 µg/ml), significantly increased [Ca2+]i (4 µg/ml), but did not significantly modify ROS. The up-regulation of annexin-V-binding following zosuquidar (4 µg/ml) treatment was significantly blunted by removal of extracellular Ca2+, by presence of p38 kinase inhibitor SB203580 (2 µM) and by presence of protein kinase C inhibitor calphostin (100 nM).

CONCLUSIONS:

Exposure of erythrocytes to zosuquidar triggers suicidal erythrocyte death with erythrocyte shrinkage and erythrocyte membrane scrambling, an effect involving Ca2+ entry and requiring activity of SB203580 and calphostin sensitive kinases.

化学结构

52003 - Zosuquidar trihydrochloride | CAS 167465-36-3

Quick inquiry

Change